Background and purpose
The incidence of malignant tumors has increased rapidly in recent years, especially in China. According to a report on cancer incidence and mortality in different areas of China, 3.8 million new malignant tumor cases were diagnosed in 2014. The crude incidence of malignant tumors in 2014 was 278.1/10 5 , whereas the crude mortality was 167.89/10 5 . 1 Therefore, more effective cancer treatments are needed. VEGF was first identified by Folkman et al in the 1970s. 2 Briefly, VEGF, which is mitogenic for endothelial cells and is responsible for the formation of new capillaries, plays an important role in tumor growth and metastasis. 2, 3 The physiological VEGF family consists of six growth factors, namely VEGF-A, VEGF-B, VEGF-C, submit your manuscript | www.dovepress.com
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sun et al VEGF-D, VEGF-E, and PLGF. The VEGFR family includes three protein tyrosine kinases: VEGFR-1 (Flt-1), VEGFR-2 (Flt-1/KDR), and VEGFR-3 (Flt-4). The combination of VEGF and VEGFR induces angiogenesis and vasculogenesis through p38MAPK, Raf/MEK/ERK, and PI3K/PKB signaling pathways. 4, 5 Given that VEGFR-2 plays a more important role in the signaling pathways, small-molecule tyrosine kinase inhibitors mostly target VEGFR-2.
Apatinib, also known as YN968D1, is a novel, oral, smallmolecule tyrosine kinase inhibitor that targets VEGFR-2 as well as c-Kit and c-SRC tyrosine kinases. 6 Apatinib was approved and launched in China in 2014 for subsequentline treatment of gastric cancer. 7 Recent clinical trials have revealed its broad-spectrum anticancer effect. However, most recent studies of apatinib have involved single-arm studies with insufficient cases, different doses of drugs, and different incidences of adverse events (AEs), resulting in a lack of accurate measurement of the efficacy and safety of apatinib. Thus, we performed this meta-analysis to evaluate the efficacy and safety of the novel VEGFR-2 inhibitor apatinib.
Methods search strategy for studies
From April 2018 to May 2018, two authors (Sun DT and Hou HL) searched five databases independently, namely PubMed, ScienceDirect, ClinicalTrials.gov, China National Knowledge Infrastructure (CNKI), and Cochrane Library. All MeSH terms of the keywords (apatinib, YN968D1) were used in the search.
Any disagreement regarding study inclusion was resolved through discussion by all authors. In addition, we contacted the corresponding authors of some of the studies if the databases failed to provide sufficient information.
literature selection criteria
All clinical trials that evaluated the efficacy and safety of apatinib in the treatment of solid tumors were considered eligible for the analysis. Two authors (Sun DT and Hou HL) completed the screening of the literature independently. The inclusion criteria were as follows: 1) study types -Phase II clinical trials or retrospective analysis; 2) participant typespatients with solid tumors; 3) intervention types -patients were treated with apatinib only with different doses; 4) outcome measure types -disease control rate (DCR), objective response rate (ORR), the incidence of $ grade 3 AEs, or at least one of these outcomes should be provided in the included studies; and 5) full text was available.
The exclusion criteria were as follows: studies were case reports, reviews, or meta-analyses, duplicates, or involved animal or cell experiments, and full text was not available via other means.
Data extraction
Two authors (Sun DT and Hou HL) completed the related literature data extraction independently. The following data were extracted: study ID, cancer types, number of patients, dose and frequency of apatinib treatment, disease baseline before apatinib treatment, Eastern Cooperative Oncology Group status, and study phase. The details of the 21 studies included are presented in Table 1 . In addition, we extracted the research indicators selected by this meta-analysis, including ORR (ORR = complete response [CR] + partial response [PR]), DCR (DCR = CR + PR + stable disease), and the incidence of $ grade 3 AEs. The results of data extraction were discussed by all authors.
Quality assessment
Two authors (Zhang CT and Zhang XC) assessed the quality of the studies independently after reading the full text of each study. We used the Newcastle-Ottawa Scale (NOS) to assess the quality of non-randomized controlled trials in this metaanalysis. 29 The quality of a study was considered "poor" if the NOS score was ,4. If the score was 4-6, we considered the study to be of "moderate" quality. A study with a score of 7-9 was considered to be of "high quality". The NOS scores of the 21 studies included are presented in Table 1 , and the quality assessment details are presented in Table 2 .
statistical analysis
All statistical analyses in this meta-analysis were performed using Stata 14.0 software (Stata Corp., College Station, TX, USA). The results were expressed as incidences and 95% CIs. In this meta-analysis, we used a random-effect model to perform the statistical analyses, and chi-squared test and I 2 statistic were used to assess the inter-study heterogeneity.
A P-value .0.1 and I
2
,50% indicated that the heterogeneity was not statistically significant. If the P-value was ,0.1 and I 2 was .50%, significant heterogeneity was noted between the studies. Therefore, subgroup analyses were used to assess the heterogeneity. Begg's and Egger's tests were used to evaluate the publication bias in this meta-analysis. 
Meta-analysis results
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The efficacy and safety of apatinib for refractory malignancies searches (PubMed 166, CNKI 329, Cochrane Library 47, ScienceDirect 150, ClinicalTrials.gov 187). Then, 537 references remained after duplicates were removed. Twenty-nine references remained after the first screening. Eight studies were excluded based on the following reasons: four were case reports or case series, one was a duplicate, and three involved cell experiments. Finally, 21 studies with a total of 735 patients were included for the assessment of efficacy and safety of apatinib.
The efficacy of apatinib Apatinib in lung cancer
Six studies with a total of 230 patients evaluated the efficacy of apatinib in lung cancer. The pooled DCR of apatinib for lung cancer patients was 82% (95% CI: 77%-87%; Figure 2A ). The pooled ORR of apatinib for lung cancer patients was 20% (95% CI: 14%-25%). Subgroup analysis revealed that patients who were administered a 500 mg dose of apatinib exhibited an increased ORR compared with patients who received a ,500 mg dose (23%, 95% CI: 16%-29% vs 16%, 95% CI: 8%-23%; Figure 2B ).
Apatinib in liver cancer
Three studies with a total of 188 patients evaluated the efficacy of apatinib in liver cancer. The pooled DCR of apatinib for liver cancer patients was 51% (95% CI: 37%-64%). Subgroup analysis revealed that patients who received $750 mg apatinib 
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The efficacy and safety of apatinib for refractory malignancies exhibited an increased DCR compared with patients who received ,750 mg (62%, 95% CI: 53%-71% vs 33%, 95% CI: 19%-48%; Figure 3A ). The pooled ORR of apatinib for liver cancer patients was 18% (95% CI: 13%-24%; Figure 3B ).
Apatinib in gastric cancer
Five studies with a total of 129 patients evaluated the efficacy of apatinib in gastric cancer. The pooled DCR of apatinib for gastric cancer patients was 66% (95% CI: 52%-79%). Subgroup analysis demonstrated that patients who received 850 mg apatinib exhibited an increased DCR compared with those patients who were administered 500 mg apatinib (79%, 95% CI: 68%-89% vs 56%, 95% CI: 40%-72%; Figure 4A ). The pooled ORR of apatinib for gastric cancer patients was 10% (95% CI: 5%-15%; Figure 4B ).
Apatinib in breast cancer
Three studies with a total of 85 patients evaluated the efficacy of apatinib in breast cancer. The pooled DCR of apatinib for breast cancer patients was 66% (95% CI: 55%-76%; Figure 5A ). The pooled ORR of apatinib for lung cancer patients was 16% (95% CI: 6%-26%). Subgroup analysis revealed that patients who were administered an 850 mg dose of apatinib exhibited an increased ORR compared with those patients who received ,850 mg apatinib (40%, 95% CI: 4%-76% vs 14%, 95% CI: 4%-23%; Figure 5B ).
Apatinib in colorectal cancer
Four studies with a total of 103 patients evaluated the efficacy of apatinib in colorectal cancer. The pooled DCR of apatinib for breast cancer patients was 79% (95% CI: 70%-87%; Figure 6A ). The pooled ORR of apatinib for lung cancer patients was 13% (95% CI: 7%-20%; Figure 6B ).
The safety of apatinib
AEs mostly occurred in every patient treated with apatinib (84% CI: 77%-92%; Figure 7A) ; however, most were of 
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sun et al grades 1-2 and were well tolerated and controlled, including secondary hypertension, hand-foot syndrome, proteinuria, fatigue, mucositis, anemia, leukopenia, thrombocytopenia, increased bilirubin, increased transaminase, diarrhea, vomiting, and rashes. The most common grade 3-4 AEs included secondary hypertension (7% CI: 5%-10%; Figure 7B ), handfoot syndrome (6% CI: 3%-8%; Figure 7C ), and proteinuria (4% CI: 2%-7%; Figure 7D ).
Publication bias
Egger's and Begg's tests were performed to evaluate the publication bias of all results in this meta-analysis. The test results were consistent with most of the results in this metaanalysis except the ORR of lung cancer (Egger's test: 0.012; Begg's test: 0.260). Given that Egger's test is more sensitive than Begg's test in evaluating publication bias, 30 we considered that publication bias exists for the ORR results of lung 
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sensitivity analysis
The results of sensitivity analysis revealed no significant differences after omitting any one of the studies included, indicating that the results of this meta-analysis were robust. The results of sensitivity analysis are presented in Figures S1-S13.
Discussion
Apatinib is a selective inhibitor of VEGFR-2 with broadspectrum anticancer effect and is also stated to be involved in the regulation of autophagy. 31 This meta-analysis involving 21 studies evaluated the efficacy and safety of apatinib in five major types of solid tumors, namely lung cancer, liver cancer, gastric cancer, breast cancer, and colorectal cancer. The pooled results for the efficacy of apatinib in the treatment of different types of solid tumors revealed that apatinib exhibited good disease control (DCR: lung cancer 82%, liver cancer 51%, gastric cancer 66%, breast cancer 66%, colorectal cancer 79%; ORR: lung cancer 20%, liver cancer 18%, gastric cancer 10%, breast cancer 16%, colorectal cancer 13%). In addition, it was likely that a higher dose of apatinib resulted in an increased ORR in lung cancer (500 mg, 23% vs ,500 mg, 16%) and breast OncoTargets and Therapy 2018:11 submit your manuscript | www.dovepress.com
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The efficacy and safety of apatinib for refractory malignancies cancer (850 mg, 40% vs ,850 mg, 14%), and an increased DCR in liver cancer ($750 mg, 62% vs ,750 mg, 33%) and gastric cancer (850 mg, 79% vs 500 mg, 56%). Although AEs appeared in 84% of patients in this metaanalysis, most were of grades 1-2 and were well tolerated and controlled. The most common grade 3-4 AEs were hypertension (7%), hand-foot syndrome (6%), and proteinuria (4%). Importantly, there were no significant differences in these grade 3-4 AEs with higher doses of apatinib (500, 750, and 850 mg).
In addition to the five major types of solid tumors reported in this meta-analysis, the efficacy of apatinib in other types of solid tumors was also demonstrated by clinical trials. The clinical trials of Li and Wang 32 and Miao et al 33 revealed that apatinib is efficacious in esophageal cancer (DCR: 74.2%; ORR: 24.2%) and ovarian cancer (DCR: 68.9%; ORR: 41.4%), respectively. Apatinib was also found to be effective in prostate cancer 34 and thyroid cancer. Admittedly, our meta-analysis has some limitations. Given that apatinib is a novel VEGFR-2 inhibitor produced in China, the participants of studies included in this metaanalysis were all Asians. However, some clinical trials have been undergoing in the USA, such as NCT03407976, NCT03396211, and NCT03042611. More data on the efficacy of apatinib in different populations will soon be obtained in the next few years. The efficacy of apatinib for other races must be confirmed by more clinical trials. In addition, publication bias existed in several results of this meta-analysis, including the ORR of lung cancer and the incidence of grade 3-4 hypertension and hand-foot syndrome. Therefore, more clinical trials are needed to confirm our results.
In conclusion, this meta-analysis suggests that patients treated with apatinib exhibited good disease control. A higher dose of apatinib (500, 750, and 850 mg) significantly increased the ORR and DCR. AEs of apatinib were
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The efficacy and safety of apatinib for refractory malignancies noted in 84% of participants. However, most AEs were of grades 1-2 and were well tolerated and controlled. The incidences of the three most common grade 3-4 AEs were low (hypertension: 7%; hand-foot syndrome: 6%; proteinuria: 4%), and there were no significant differences between the higher-dose and lower-dose groups. Additional clinical trials are needed to update our study and compare the efficacy of apatinib with other VEGFR-2 inhibitors and other small-molecule tyrosine kinase inhibitors to provide more information to patients.
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